Home Lexicon Announces Focus On Late-Stage Development Programs And Preparation For Commercialization
 

Keywords :   


Lexicon Announces Focus On Late-Stage Development Programs And Preparation For Commercialization

2014-02-05 07:12:10| drugdiscoveryonline News Articles

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today it is focusing its resources on its late-stage drug development programs, principally LX4211 for diabetes and telotristat etiprate (LX1032) for carcinoid syndrome, and preparation for the transition to commercialization

Tags: development focus programs preparation

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
02.11Subtropical Storm Patty Graphics
02.11Atlantic Tropical Weather Outlook
02.11Eastern North Pacific Tropical Weather Outlook
02.11Tropical Storm Lane Graphics
02.11Subtropical Storm Patty Graphics
02.11Tropical Storm Lane Forecast Discussion Number 4
02.11Subtropical Storm Patty Wind Speed Probabilities Number 2
02.11Summary for Tropical Storm Lane (EP3/EP132024)
More »